{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:53:33Z","timestamp":1791024813495,"version":"4.1.0"},"reference-count":86,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent developments in hidradenitis suppurativa (HS) have focused on targeting key inflammatory pathways implicated in the pathogenesis of the disease, including interleukin (IL)\u201017, IL\u20101, tumour necrosis factor (TNF), Janus kinase (JAK) and tyrosine kinase 2 (TYK2) signalling as well as innate immune mechanisms such as neutrophil activation and complement pathways. Novel biologics, dual cytokine\u2010inhibition strategies and bispecific agents represent an emerging therapeutic paradigm. Small\u2010molecule inhibitors, including JAK1 and TYK2 inhibitors, offer the potential advantage of oral administration and broader immunomodulatory effects. Therapies targeting alternative mechanisms, including B\u2010cell modulation, complement inhibition, chemokine signalling and intracellular pathways, are also being actively investigated. While some agents have shown encouraging results in selected HS trials, including responses at higher thresholds, such as IHS4\u201075 or IHS4\u201090, findings remain heterogeneous. Some trials have not met their primary endpoints, highlighting the challenges of translating mechanistic rationale into consistent clinical benefit. Overall, the expanding therapeutic pipeline in HS reflects a shift towards precision medicine and pathway\u2010specific interventions. This review aims to summarize the upcoming treatments in hidradenitis suppurativa and to outline the future therapeutic landscape of the disease.<\/jats:p>","DOI":"10.1111\/jdv.70749","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:15:08Z","timestamp":1791022508000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Upcoming novel treatments for hidradenitis suppurativa: An overview of the pipeline"],"prefix":"10.1111","author":[{"given":"Thrasyvoulos","family":"Tzellos","sequence":"first","affiliation":[{"name":"Department of Dermatology NLSH Bod\u00f8  Bod\u00f8 Norway"},{"name":"Department of Clinical Medicine Faculty of Health Sciences, UiT \u2013 The Arctic University of Norway  Troms\u00f8 Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3936-8374","authenticated-orcid":false,"given":"Aikaterini I.","family":"Liakou","sequence":"additional","affiliation":[{"name":"First Department of Dermatology and Venereology \u201cAndreas Sygros\u201d Hospital for Venereal and Cutaneous Diseases, National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-6785","authenticated-orcid":false,"given":"Patricia","family":"Garbayo\u2010Salmons","sequence":"additional","affiliation":[{"name":"Dermatology Department Parc Taul\u00ed Hospital Universitari. Institut d'Investigaci\u00f3 i Innovaci\u00f3 Parc Taul\u00ed (I3PT\u2010CERCA), Universitat Aut\u00f2noma de Barcelona  Sabadell Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology Union Hospital, Tongji Medical College, Huazhong University of Science and Technology  Wuhan China"},{"name":"Hubei Engineering Research Center of Skin Disease Theranostics and Health, Huazhong University of Science and Technology  Wuhan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2397-6316","authenticated-orcid":false,"given":"Eran","family":"Shavit","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Wolfson Medical Center  Holon Israel"},{"name":"Gray Faculty of Medical and Health Sciences, Gray School of Medicine, Tel\u2010Aviv, University  Tel\u2010Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-2045","authenticated-orcid":false,"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology University of Florence  Florence Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1014163"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.0201"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2503"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14214"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.02.742"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18632"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18163"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010025\u201001487\u2010y"},{"key":"e_1_2_12_14_1","unstructured":"KimballAB KirbyB BecharaFG PorterMJ PrensE JemecGBE et\u00a0al.Efficacy and safety of the IL\u201017A\u2010 and IL\u201017F\u2010inhibiting Nanobody\u00ae sonelokimab in patients with moderate\u2010to\u2010severe hidradenitis suppurativa (HS); week 24 results from the phase 2 MIRA trial. In: Presented at: American Academy of Dermatology annual meeting; 8\u201312 March 2024; San Diego California. Abstract 56 014."},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.878"},{"key":"e_1_2_12_16_1","unstructured":"KirbyB.Sonelokimab in moderate\u2010to\u2010severe HS: topline efficacy and safety results from the phase 3 VELA\u20101 and VELA\u20102 trials. Presentation S\u201010\u201004. Presented at: European hidradenitis Suppurativa foundation (EHSF) congress; February 4\u20136 2026; Malta."},{"key":"e_1_2_12_17_1","unstructured":"SzepietowskiJC FrewJW Gonz\u00e1lez\u2010Cantero\u00c1 InramJR JemecGBE KirbyB et\u00a0al.Sonelokimab in moderate\u2010to\u2010severe HS: clinically meaningful IHS4 outcomes from the phase 3 VELA\u20101 and VELA\u20102 trials. Poster A\u201009\u201019. Presented at: European Hidradenitis Suppurativa Foundation (EHSF) Conference; February 4\u20136 2026; Malta."},{"key":"e_1_2_12_18_1","unstructured":"KirbyB GooderhamMJ GottliebAB HamzaviIH HsiaoJL JemecGBE et\u00a0al.High levels of pain response with sonelokimab in VELA\u20101 and VELA\u20102: two phase 3 trials in patients with moderate\u2010to\u2010severe hidradenitis suppurativa. Poster A\u201009\u201020. Presented at: European hidradenitis Suppurativa foundation (EHSF) conference; February 4\u20136 2026; Malta."},{"key":"e_1_2_12_19_1","unstructured":"IngramJR DaveluySD GooderhamMJ GottliebAB HsiaoJL Lev\u2010TovH et\u00a0al.HiSQOL outcomes are rapidly improved with sonelokimab in the phase 3 VELA\u20101 and VELA\u20102 trials: HS\u2010specific quality\u2010of\u2010life scores in patients with moderate\u2010to\u2010severe hidradenitis suppurativa. Poster A\u201009\u201018. Presented at: European hidradenitis Suppurativa foundation (EHSF) conference; February 4\u20136 2026; Malta."},{"key":"e_1_2_12_20_1","unstructured":"KimballAB PorterM GooderhamMJ HamzaviIH HsiaoJL KirbyB et\u00a0al.Sonelokimab in moderate\u2010to\u2010severe HS: long\u2010term results through week 40 of two phase 3 trials. Late\u2010breaking research session 2 (S034). Presented at: American Academy of Dermatology (AAD) annual meeting; Denver Colorado2026."},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010024\u201000687\u2010w"},{"key":"e_1_2_12_22_1","unstructured":"PappK IzokibepA.Novel IL\u201017A inhibitor demonstrates HiSCR100 responses in moderate\u2010to\u2010severe hidradenitis suppurativa: open\u2010label part a results of a phase 2b\/3 study.2023Annual meeting 17\u201321 march New Orleans USA."},{"key":"e_1_2_12_23_1","unstructured":"Affibody AB.Positive phase 3 results in hidradenitis suppurativa further strengthen competitive profile of izokibep. Press release. Solna Sweden; August 132024."},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","unstructured":"PappKA BecharaFG PorterML FormanSB SofenH SzepietowskiJC et\u00a0al.Efficacy of izokibep a novel interleukin\u201017A inhibitor in moderate\u2010to\u2010severe hidradenitis suppurativa: week 32 results from a randomized double\u2010blind placebo\u2010controlled phase 3 study. Poster 71 352. Presented at: American Academy of Dermatology (AAD) annual meeting; Denver CO2026.","DOI":"10.1016\/j.jaad.2026.04.781"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom14020175"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad225"},{"key":"e_1_2_12_27_1","article-title":"Lutikizumab in adults with moderate to severe hidradenitis Suppurativa after anti\u2010TNF therapy failure: a phase 2 randomized clinical trial","volume":"18","author":"Kimball AB","year":"2026","journal-title":"JAMA Dermatol"},{"key":"e_1_2_12_28_1","unstructured":"BecharaFG Giamarellos\u2010BourboulisE TzellosT WisemanM VilarrasaE SawickiKT et\u00a0al.Characterization of the IHS4 response to lutikizumab treatment in patients with moderate\u2010to\u2010severe hidradenitis suppurativa (HS).2025Abstract No 7909 Presented at: European Academy of Dermatology and Venereology Congress 2025; Paris France."},{"key":"e_1_2_12_29_1","unstructured":"ClinicalTrials.gov.A phase III multicenter randomized double blind placebo controlled study to evaluate the efficacy and safety of lutikizumab in adult and adolescent subjects with moderate to severe hidradenitis suppurativa (Intrepid). Available from:https:\/\/clinicaltrials.gov\/study\/NCT06468228"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.046"},{"key":"e_1_2_12_31_1","unstructured":"Incyte Corporation.Incyte announces positive topline results from two phase 3 clinical trials of povorcitinib in patients with hidradenitis suppurativa. Available from:https:\/\/investor.incyte.com\/news\u2010releases\/news\u2010release\u2010details\/incyte\u2010announces\u2010positive\u2010topline\u2010results\u2010two\u2010phase\u20103\u2010clinical"},{"key":"e_1_2_12_32_1","unstructured":"Incyte Corporation.Incyte announces new Positive 54\u2010Week late\u2010breaking data for povorcitinibIn in hidradenitis suppurativa at the 2026 american academy of dermatology (AAD) annual meeting. Available from:https:\/\/investor.incyte.com\/news\u2010releases\/news\u2010release\u2010details\/incyte\u2010announces\u2010new\u2010positive\u201054\u2010week\u2010late\u2010breaking\u2010data"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.149"},{"key":"e_1_2_12_34_1","unstructured":"ClinicalTrials.gov.A randomized subject and investigator blinded placebo\u2010controlled and multi\u2010center platform study to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa. Available from:https:\/\/clinicaltrials.gov\/study\/NCT03827798"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.10.015"},{"key":"e_1_2_12_36_1","unstructured":"BecharaFG PrensEP GudjonssonJE BangB GhanshaniSA LoescheC et\u00a0al.Remibrutinib in patients with moderate to severe hidradenitis suppurativa: international hidradenitis Suppurativa severity scoring system (IHS4) outcomes from a randomised phase 2 double\u2010blind placebo\u2010controlled platform study [oral presentation]. 15th European hidradenitis Suppurativa foundation (EHSF) 4\u20136 February Malta2026."},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","unstructured":"KimballAB PrensEP BecharaFG GudjohnssonJE BangB GhanshaniSA et\u00a0al.Remibrutinib in patients with moderate to severe hidradenitis suppurativa: patient\u2010reported outcomes from a randomized phase 2 double\u2010blind placebo\u2010controlled platform study [ePoster]. American Academy of Dermatology (AAD) Annual Meeting; Mar 7\u201311; Orlando FL USA2025.","DOI":"10.1016\/j.jaad.2025.05.1142"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043391"},{"issue":"1","key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamadermatol.2024.4688","article-title":"Safety and efficacy of Deucravacitinib in moderate to severe plaque psoriasis for up to 3\u2009years","volume":"161","author":"Armstrong AW","year":"2024","journal-title":"JAMA Dermatol"},{"key":"e_1_2_12_40_1","unstructured":"ClinicalTrials.gov.Evaluating the safety and efficacy of deucravacitinib compared to placebo hidradenitis suppurativa (HS). Available from:https:\/\/clinicaltrials.gov\/study\/NCT05997277"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00600"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.05.014"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228436"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098428"},{"key":"e_1_2_12_45_1","unstructured":"ClinicalTrials.gov (NCT07244263).A study of zasocitinib in adults with hidradenitis suppurativa."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70118"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02475-9"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2025.100483"},{"issue":"1","key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12931-023-02444-z","article-title":"Dipeptidyl peptidase\u20101 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial","volume":"24","author":"Cipolla D","year":"2023","journal-title":"Respir Res"},{"issue":"14","key":"e_1_2_12_50_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1239151","article-title":"Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil\u2010mediated inflammatory disease","volume":"14","author":"Chalmers JD","year":"2023","journal-title":"Front Immunol"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5908"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17706"},{"key":"e_1_2_12_53_1","unstructured":"ClinicalTrials.gov.A study of the efficacy and safety of brensocatib in adults with moderate to severe hidradenitis suppurativa (CEDAR). NCT06685835."},{"key":"e_1_2_12_54_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1292941","article-title":"The role of the interleukin\u201036 axis and mechanism of action of spesolimab","volume":"14","author":"Hawkes JE","year":"2023","journal-title":"Front Immunol"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16019"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae144"},{"key":"e_1_2_12_59_1","unstructured":"ClinicalTrials.gov.A study to test spesolimab in people with hidradenitis suppurativa (Lunsayil\u20101). Available from:https:\/\/clinicaltrials.gov\/study\/NCT05819398"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061303"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000526"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13730\u2010025\u201000991\u20106"},{"key":"e_1_2_12_63_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2021.07.121","article-title":"LB791 Avacopan, a highly selective small molecule inhibitor of c5a receptor, in patients with hidradenitis suppurativa: initial results from a randomized, double\u2010blind, placebo\u2010controlled, phase 2 study (aurora)","volume":"141","author":"Kirby JS","year":"2021","journal-title":"J Invest Dermatol"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/01926233221100168"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01211-X"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2023.11.013"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005557"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251396115"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17010091"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21744"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20222"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.046"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116562"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010022\u201001764\u20106"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20880"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128897"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4800"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010026\u201009152\u20108"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(25)00071\u20108"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12621"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.11.010"},{"issue":"9","key":"e_1_2_12_82_1","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.3389\/fimmu.2018.02965","article-title":"Hidradenitis Suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"14","author":"Vossen ARJV","year":"2018","journal-title":"Front Immunol"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203672"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4926"},{"issue":"2","key":"e_1_2_12_85_1","first-page":"569","article-title":"High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin\u20102 expression","volume":"149","author":"Navrazhina K","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.035"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242317014"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70749","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:15:13Z","timestamp":1791022513000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":86,"alternative-id":["10.1111\/jdv.70749"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70749","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"2026-06-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdv.70749"}}